Transparency in Anesthesiology Billing
Most anesthesiologists collect less than they are entitled to because the billing and collections process in America is fundamentally broken. It is also difficult for anesthesiologists to evaluate the performance of their billing company. Are they coding clean claims? Are they actually taking the time to go after everything that is owed? Download this how-to guide to determine if you are with the right billing company.
Sponsored by:
Fusion Anesthesia Solutions, LLC
Address: 225 S Executive Dr. Brookfield, WI 53005
Phone: 262-933-3730
Contact Name: Jake Buss
Email: jbuss@fusionhsllc.com
Website: http://www.fusionanesthesia.com
Transparency in Anesthesiology Billing
Evaluating the performance of a current or prospective billing company is nearly impossible for most anesthesiologists. The truth is, medical billing isn't rocket science, but it's not a commodity product either. As a result, most anesthesiologists collect less than they are entitled to receive for their services because the billing and collections process in America is fundamentally broken. And to make matters worse, very few billing companies have the commitment, or infrastructure in place, to correct this.
Too many anesthesiologists are being taken advantage of by both the impersonal behemoths of the industry and smaller "discount" billing companies. These companies bill the easy money and leave the rest- up to 5-15% of the collectible total-on the table. That's your money they aren't collecting.
Here's everything you need to know to evaluate your billing company and understand if you're missing a significant portion of your potential earnings.
Fill out the form to read it now!
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
